Literature DB >> 23992819

Orthodontic occlusal reconstruction after conservative treatment of unicystic ameloblastoma in an adolescent patient: 10-year follow-up.

Yuko Tomita1, Shingo Kuroda, Takumi Takahashi, Ritsuko Ohura, Eiji Tanaka.   

Abstract

Conservative treatment of an ameloblastoma often requires an occlusal reconstruction. In this article, we report the successful interdisciplinary treatment of a 14-year-old girl with a unicystic ameloblastoma in the mandible. One year after the marsupialization, enucleation with bone curettage was performed with extraction of the impacted third molar, but the proximal second molar could be maintained. The conservative treatment required long-term use of an obturator, and it caused a total open bite. Additionally, the patient genetically had a Class II malocclusion with severe crowding. Consequently, orthodontic treatment was performed after 4 premolar extractions. There was no recurrence of the ameloblastoma 10 years after the enucleation.
Copyright © 2013 American Association of Orthodontists. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23992819     DOI: 10.1016/j.ajodo.2012.06.021

Source DB:  PubMed          Journal:  Am J Orthod Dentofacial Orthop        ISSN: 0889-5406            Impact factor:   2.650


  3 in total

1.  Conservative Management of Unicystic Ameloblastoma in Young Patients: A Prospective Single-Center Trial and Review of Literature.

Authors:  Mitsu Meshram; Lalit Sagarka; Jigar Dhuvad; Sonal Anchlia; Siddharth Vyas; Harsh Shah
Journal:  J Maxillofac Oral Surg       Date:  2016-12-20

2.  Conservative management (marsupialization) of unicystic ameloblastoma: literature review and a case report.

Authors:  Jwayoung Kim; Eunkyung Nam; Sukho Yoon
Journal:  Maxillofac Plast Reconstr Surg       Date:  2017-12-25

3.  Occlusal reconstruction of a patient with ameloblastoma ablation using alveolar distraction osteogenesis: a case report.

Authors:  Yoshihito Ishihara; Hikaru Arakawa; Akiyoshi Nishiyama; Hiroshi Kamioka
Journal:  Head Face Med       Date:  2020-06-02       Impact factor: 2.151

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.